Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2006

View Archived Issues

Q1 developments at Ono

sanofi-aventis: H1 review

New KCa channel activator a promising strategy for micturition control

Novel treatment options for metabolic disorders described in recent patents

sanofi-aventis patents novel cannabinoid CB1 receptor antagonists

New strategies for treatment of glaucoma reported in recent patents

New anxiolytics disclosed in a recent Ono patent

Alzheimer's disease candidate AL-108 begins phase Ib study

Phase II study of GV-1001 in hepatocellular carcinoma cleared to begin in France

Obesity drug candidate BVT-74316 enters phase I testing

Positive phase I results for universal allergy immunotherapy RP-01

Enrollment completed in iloperidone and VEC-162 phase III trials

MLN-0415 studied in phase I for inflammatory disorders

SBIR grant to support Velcura's research into processes in bone formation

Novel delta opioid agonist ADL-5859 begins phase I study

ChemDiv and Yale receive NIH grant for adrenal gland disorder research

Roche discontinues codevelopment of daclizumab in asthma

New preclinical data for shingles compound FV-100

Genzyme to initiate tender offer for AnorMED

MolecularMD to support phase II study of Ablvax

MediGene to acquire Avidex

PR-104, a hypoxia-activated prodrug under clinical development for cancer

Bristol-Myers Squibb report on new potent and selective FXa inhibitor

GSK reports on SB-737050A, their new targeted lead candidate for schizophrenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...